Published on Saturday October 05, 2024

Smooth Drug Development September 2024 News Release

Monthly News – September 2024

At Smooth Drug Development, we are excited to share the latest updates and achievements from September 2024:

New Projects

We are delighted to announce several new collaborations:

Bioequivalence Studies:

Awarded two contracts for bioequivalence studies with Bempedoic acid, conducted under fasting and postprandial conditions.
Secured two contracts for bioequivalence trials involving Umifenovir at 200 mg and 50 mg dosages.

Medical Writing Services:

Agreements signed for the following trials: Indapamide – Bioequivalence (BE) trial, Brentuximab Vedotin – Phase I trial, Benzydamine + Cetylpyridinium chloride – Phase III trial

Clinical and Scientific Departments News:

Successfully enrolled 34 subjects in a bioequivalence study in oncology.
Enrolled 6 patients in the Pembrolizumab clinical trial.

These milestones underscore our team’s dedication to advancing clinical research and ensuring seamless project execution.

Thank you for your continued support and interest in Smooth Drug Development. Stay tuned for more updates next month as we continue to push the boundaries of excellence in clinical research!